Bile acids are being reframed as endocrine signals in the aging liver
Bile acids have moved far beyond their old reputation as simple detergents for fat digestion. In aging-related liver disease, they now sit closer to a hormone network, influencing glucose handling, lipid balance, immune tone, and energy regulation through receptors such as FXR and TGR5. The review positions this biology at the center of hepatic aging, arguing that changes in bile acid synthesis and signaling are not just downstream consequences of liver dysfunction but active participants in it.
Aging reshapes bile acid metabolism at several levels at once. Synthesis changes, enterohepatic circulation shifts, hydrophobicity can increase, microbial conversion changes, and receptor responsiveness may weaken or become dysregulated. In a liver already exposed to mitochondrial stress, endoplasmic reticulum stress, defective autophagy, and immune imbalance, those shifts can compound cellular injury. The result is a feedback loop in which altered bile acid signaling accelerates senescence while senescence further distorts bile acid homeostasis.
This is not a narrow metabolic story. It reaches into inflammaging, the chronic low-grade inflammatory state that develops with age, and into the broader vulnerability that older livers face when exposed to steatotic, toxic, viral, or autoimmune injury.
FXR and TGR5 sit at the center of the metabolic response
The two best-known receptors in this pathway are FXR, a nuclear receptor, and TGR5, a membrane receptor. Their roles are complementary but distinct. FXR helps regulate bile acid synthesis and broader metabolic programs, while TGR5 links bile acid signaling to energy balance and immune modulation. In aging liver disease, both pathways become more than biochemical curiosities; they are part of the machinery that determines whether the liver adapts or decompensates.
The review emphasizes that bile acids are not uniform molecules. Different species have different receptor preferences, and their biological effects depend on structure, abundance, and context. Hydrophobic species may carry greater stress potential, while changes in microbial biotransformation can shift the bile acid pool toward patterns that worsen inflammation or cellular injury. The liver does not encounter bile acids as a static substance pool; it sees a changing endocrine signal shaped by age, microbiota, and disease state.
One sentence captures the clinical implication directly: bile acid signaling can either stabilize hepatic metabolism or intensify age-related injury.
Gut microbiota changes amplify bile acid remodeling
The gut microbiota is inseparable from bile acid biology. Microbial enzymes transform primary bile acids into secondary species, and those transformations alter the signaling landscape that reaches the liver. Aging changes the microbiome, and those changes feed back into bile acid composition. The review treats this gut-liver crosstalk as a core mechanism, not a side pathway.
As the microbial ecosystem shifts with age, the balance of bile acid species can change as well, affecting receptor engagement and downstream inflammatory signaling. That has implications for the frailty of the aging liver microenvironment, where chronic exposure to altered bile acid pools may help maintain a state of persistent stress. In practical terms, this means that age-associated liver disease cannot be understood by measuring hepatocytes alone. The intestinal ecosystem, bile acid transformation, and receptor-level response all belong to the same disease circuit.
Senescence pathways link bile acid injury to liver vulnerability
The review draws a direct line between dysregulated bile acid signaling and cellular programs associated with senescence. Mitochondrial stress can rise, endoplasmic reticulum stress can accumulate, autophagy can falter, and immune dysfunction can deepen. These disruptions do not remain isolated. They shape the senescence-associated secretory phenotype, which then reinforces inflammation and tissue damage.
This bidirectional relationship matters because it explains why aging livers often become less resilient even before overt decompensation appears. Bile acid abnormalities are not merely markers of deterioration. They can participate in the biology that makes the liver more susceptible to injury from metabolic overload, alcohol, chronic viral infection, or autoimmune attack. The aged liver becomes a system in which endocrine signaling, cellular stress, and immune dysfunction move together.
Disease-specific implications extend across major liver disorders
The review applies this framework to several aging-related liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), autoimmune liver diseases (AILD), chronic hepatitis B (CHB), and hepatocellular carcinoma (HCC). The common thread is not that these conditions are identical, but that bile acid remodeling may influence their course through shared metabolic and inflammatory pathways.
In steatotic liver disease, altered bile acid signaling may interact with lipid and glucose dysregulation. In alcohol-related injury, stress pathways and inflammatory amplification may become more prominent. In chronic viral and autoimmune disease, immune signaling becomes especially relevant. In HCC, the long arc of chronic injury, inflammation, and senescence creates a setting in which bile acid pathways may also shape carcinogenic potential.
The conceptual value of this framing is substantial. It suggests that bile acid biology deserves attention not only in classic cholestatic disorders but also in age-associated liver disease more broadly.
Therapeutic targeting is promising, but the biology is not simple
Because bile acids act through defined receptors and metabolic circuits, they present an attractive therapeutic target. Modulating the FXR-TGR5 axis could, in principle, alter metabolic balance, inflammatory tone, and cellular stress responses. The review is careful, however, not to portray this pathway as an easy fix. Bile acid signaling is deeply contextual, and its effects depend on species composition, receptor distribution, microbial input, and the underlying liver disease.
Therapeutic manipulation therefore carries caveats. A pathway that is beneficial in one context may have different consequences in another, especially in aging tissue where receptor responsiveness and homeostatic reserve are already altered. The review frames this as a major translational challenge: interventions must account for the complexity of bile acid biology rather than assume a single universal response.
The biology also argues for precision. Age, disease phenotype, microbiota composition, and hepatic reserve may all influence whether bile acid-targeted therapy helps or disappoints.
A more useful model for age-associated liver disease
The main contribution of this review is conceptual clarity. It places bile acids at the intersection of endocrinology, metabolism, immunity, and aging biology, and it argues that this intersection helps explain why the liver becomes more fragile over time. In that model, bile acids are not passive byproducts of hepatic function. They are active signals that can shape the tempo of liver aging and the severity of age-related disease.
What emerges is a bidirectional system: aging changes bile acid metabolism, and altered bile acid signaling can accelerate the molecular features of aging. That loop offers a plausible explanation for why older livers are more vulnerable to multiple disease types at once.
The unanswered issue is not whether bile acids matter. It is how best to intervene in a signaling network that is tightly interwoven with metabolism, microbiota, and senescence, and how to do so without disturbing functions the liver still needs to preserve.